AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for CX3C chemokine receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P49238

UPID:

CX3C1_HUMAN

Alternative names:

Beta chemokine receptor-like 1; Fractalkine receptor; G-protein coupled receptor 13; V28

Alternative UPACC:

P49238; A0N0N6; B2R5Z4; J3KP17

Background:

CX3C chemokine receptor 1, known as CX3CR1, plays a pivotal role in immune response, inflammation, and cell adhesion. It acts as a receptor for the chemokine fractalkine, mediating leukocyte migration and exerting functions in tissue compartments. Its involvement in the recruitment of natural killer cells, regulation of inflammation in atherogenesis, and role in airway inflammation highlight its significance in immune modulation. Additionally, CX3CR1 is crucial in brain development, synaptic pruning, and gut microbiota regulation.

Therapeutic significance:

CX3CR1's association with age-related macular degeneration underscores its therapeutic potential. Understanding the role of CX3C chemokine receptor 1 could open doors to potential therapeutic strategies, particularly in treating irreversible vision loss and managing immune-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.